NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

We’ve also been very active in the DCVax, which was started at UCLA but now extended to Penn and other sites. And the interesting thing of that trial, which we reported some preliminary data, is that a large percentage of the patients are now living beyond 3 years, so that is a unique approach in that the patients own tumor creates their very individual vaccine looking at their own panel of antigens. So we’re excited by that approach and we’ll be hearing more about that in the future.

Dr. Shah: Okay, so my understanding of the DCVax is that you have to take the tissue out and then generate something against the dendritic cells within that admixture.

Dr. Brem: Yes.

Dr. Shah: Could you tell us a little bit more about where that therapy stands as of now and what kind of efficacy we're getting?

Dr. Brem: Well, a very large multi-national study was concluded and so that is going to…as the data matures, that will be going to FDA. We hope that that gets approved. We don’t know, but it’s an exciting study.

https://www.practiceupdate.com/content/select-novel-approaches-to-glioblastoma-part-2/76518

Forumreader35,

Thank you!

Steven Brem, MD is one of the 65 authors!

"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma".
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6